Taking T-Cell Oncotherapy Off-the-Shelf.
Trends Immunol
; 42(3): 261-272, 2021 03.
Article
em En
| MEDLINE
| ID: mdl-33536140
ABSTRACT
Banked allogeneic or 'off-the-shelf' (OTS) T cells from healthy human donors are being developed to address the limitations of autologous cell therapies. Potential challenges of OTS T cell therapies are associated with their allogeneic origin and the possibility of graft-versus-host disease (GvHD) and host-versus-graft immune reactions. While the risk of GvHD from OTS T cells has been proved to be manageable in clinical studies, approaches to prevent immune rejection of OTS cells are at an earlier stage of development. We provide an overview of strategies to generate OTS cell therapies and mitigate alloreactivity-associated adverse events, with a focus on recent advances for preventing immune rejection.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Doença Enxerto-Hospedeiro
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article